V
The FDA’s peptide circus is underway.
An advisory panel, stacked with RFK Jr.’s pro-peptide appointees, has voted to add BPC-157 and KPV to the bulk compounding list. This is despite FDA staff clinicians stating that there’s no convincing evidence. Central to the argument is whether allowing compounding will curtail the gray market or expose the public to unnecessary risk. Internally screaming.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
Most Popular
Most Popular
- Good riddance, Cybertruck!
- Anker’s new window-mounted camera monitors the outside of your home from within it
- I’ve reviewed almost every Android foldable this year — here’s how the iPhone Duo compares
- KPop Demon Hunters on 4K Blu-ray costs less than a month of Netflix Premium
- Why a new report on Anthropic automating AI development is alarming researchers
